
Erlocip 150mg Tablet
Salt Composition: Erlotinib
Expiry Date: 01/2028
Inclusive of all taxes
30 tablet
About The Product
non-small cell lung cancer (NSCLC) and pancreatic cancer
Erlocip 150mg Tablet is a prescription-based anticancer medicine. It is used for the treatment of pancreatic cancer and non-small cell lung cancer. This tablet has a salt constituent called 'Erlotinib,' which belongs to the drug class of 'kinase inhibitors. It stops the activity of the abnormal protein that leads to cancerous growth. Take it exactly as prescribed at the fixed time each day for better results.
Side Effects
- Side effects are unwanted symptoms that can occur from any medical treatment.
- Like other medications, the Erlocip 150mg Tablet can also have adverse effects on the body, most of which resolve without the need for medical attention.
- Some common side effects include: Abdominal pain Bone pain Breathlessness Constipation Cough Diarrhea Fatigue Fever Infection Muscle pain Nausea Rash Stomatitis (Inflammation of the mouth)
- Vomiting Weight loss Seek medical attention in case of any unusual or severe side effects immediately.
How To Use
- The doctor determines the dosage and treatment duration with Erlocip 150mg Tablet as per the patient's health condition and stage of cancer.
- This tablet should be taken orally without food.
- Don't chew or crush the tablet.
- In the case of overdose, contact your doctor immediately.
Safety Advice
Missed Doses
- If the patient misses a dose of medicine, skip it and continue with the normal schedule.
- No need to double the dose
Reference
1. Bonomi, P.
(2003). Erlotinib: a new therapeutic approach for non-small cell lung cancer.
Expert opinion on investigational drugs, 12(8), 1395-1401. 2.
Kelley, R. K., & Ko, A.
H. (2008).
Erlotinib in the treatment of advanced pancreatic cancer. Biologics: targets and therapy, 2(1), 83-95.
3. Kelley, R.
K., & Ko, A. H.
(2008). Erlotinib in the treatment of advanced pancreatic cancer.
Biologics: targets and therapy, 2(1), 83-95. 4.
Liu, V., White, D. A., Zakowski, M.
F., Travis, W., Kris, M. G., Ginsberg, M.
S., ... & Azzoli, C. G.
(2007). Pulmonary toxicity associated with erlotinib.
Chest, 132(3), 1042-1044. 5.
Scagliotti, G. V., Krzakowski, M., Szczesna, A., Strausz, J., Makhson, A., Reck, M., ... & Govindan, R.
(2012). Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non–small-cell lung cancer: a phase III trial.
Journal of clinical oncology, 30(17), 2070-2078.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
